Finally, although higher circulating levels of lipase and amylase were reported in patients on GLP-1 RA therapy in many trials, the increases were rarely higher than three or five-fold the upper limit of normal (ULN), respectively [9,10,11,12,13,14,15,16,17], returned to normal levels after medication withdrawn, and were poor predictors of AP [54]
These may include compounded GLP-based therapies, combination GLP/GIP therapies, or other prescription options when clinically appropriate
This data was vital for regulatory approval and understanding the broader physiological effects of GLP-1 receptor agonist drugs
Times have changed a bit and newer and larger studies have been done since that time